Immunohistochemical characterization of nasal-type extranodal NK/T-cell lymphoma using a tissue microarray: An analysis of 84 cases

American Journal of Clinical Pathology

Volumn 130, Issue 3, 2008, Pages 343-351

  Schwartz, Erich J ^a   Molina Kirsch, Hernan ^b   Zhao, Shuchun ^a   Marinelli, Robert J ^a   Warnke, Roger A ^a   Natkunam, Yasodha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b San Juan Hospital   (Guatemala)

Author keywords

Cell adhesion receptors; Hierarchical cluster analysis; Immunohistochemistry; Nasal type extranodal NK T cell lymphoma; Tissue microarray

Indexed keywords

CD2 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CELL MARKER; CHEMOKINE RECEPTOR CXCR3; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; GRANZYME B; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; KI 67 ANTIGEN; L SELECTIN; LEUKOSIALIN; PERFORIN; PROTEIN BCL 2; TIA1 ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIBODY SCREENING; ARTICLE; CLUSTER ANALYSIS; DIAGNOSTIC VALUE; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; IN SITU HYBRIDIZATION; NASAL TYPE NATURAL KILLER T CELL LYMPHOMA; NATURAL KILLER T CELL; NOSE CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TISSUE MICROARRAY;

ANTIGENS, CD45; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, PERIPHERAL; MICROARRAY ANALYSIS; NOSE NEOPLASMS; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 51349083269     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/V561QTM6854W4WAV     Document Type: Article

References (60)

1. Fellbaum C, Hansmann ML, Lennert K. Malignant lymphomas of the nasal cavity and paranasal sinuses. Virchows Arch A Pathol Anat Histopathol. 1989;414:399-405.
2. Frierson HF Jr, Innes DJ Jr, Mills SE, et al. Immunophenotypic analysis of sinonasal non-Hodgkin's lymphomas. Hum Pathol. 1989;20:636-642.
3. Weiss LM, Arber DA, Strickler JG. Nasal T-cell lymphoma. Ann Oncol. 1994;5(suppl 1):39-42.
4. Chan JK, Ng CS, Lau WH, et al. Most nasal/nasopharyngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol. 1987;11:418-429.
5. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501-4513.
6. Ho FC, Todd D, Loke SL, et al. Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight-year period. Int J Cancer. 1984;34:143-148.
7. Nakamura S, Suchi T, Koshikawa T, et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol. 1995;19:284-296.
8. Ng CS, Chan JK, Lo ST, et al. Immunophenotypic analysis of non-Hodgkin's lymphomas in Chinese: a study of 75 cases in Hong Kong. Pathology. 1986;18:419-425.
9. Aviles A, Rodriguez L, Guzman R, et al. Angiocentric T-cell lymphoma of the nose, paranasal sinuses and hard palate. Hematol Oncol. 1992;10:141-147.
10. van de Rijn M, Bhargava V, Molina-Kirsch H, et al. Extranodal head and neck lymphomas in Guatemala: high frequency of Epstein-Barr virus-associated sinonasal lymphomas. Hum Pathol. 1997;28:834-839.
11. Arber DA, Weiss LM, Albujar PF, et al. Nasal lymphomas in Peru: high incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol. 1993;17:392-399.
12. Quintanilla-Martinez L, Franklin JL, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. Hum Pathol. 1999;30:849-855.
13. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
14. Jacob MC, Chaperot L, Mossuz P, et al. CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica. 2003;88:941-955.
15. Petrella T, Dalac S, Maynadie M, et al. CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol. 1999;23:137-146.
16. Khoury JD, Medeiros LJ, Manning JT, et al. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer. 2002;94:2401-2408.
17. Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leuk Res. 1999;23:615-624.
18. Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997;90:2417-2428.
19. Jaffe ES, Chan JK, Su IJ, et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas: definitions, differential diagnosis, and epidemiology. Am J Surg Pathol. 1996;20:103-111.
20. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216-221.
21. Kim BS, Kim TY, Kim CW, et al. Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy: result of chemotherapy in NK/T-cell lymphoma. Acta Oncol. 2003;42:779-783.
22. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100:366-375.
23. Chan AC, Ho JW, Chiang AK, et al. Phenotypic and cytotoxic characteristics of peripheral T-cell and NK-cell lymphomas in relation to Epstein-Barr virus association. Histopathology. 1999;34:16-24.
24. Ho FC, Choy D, Loke SL, et al. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol. 1990;21:1041-1050.
25. Kanavaros P, Lescs MC, Briere J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood. 1993;81:2688-2695.
26. Ng CS, Lo ST, Chan JK, et al. CD56+ putative natural killer cell lymphomas: production of cytolytic effectors and related proteins mediating tumor cell apoptosis? Hum Pathol. 1997;28:1276-1282.
27. Ohsawa M, Nakatsuka S, Kanno H, et al. Immunophenotypic and genotypic characterization of nasal lymphoma with polymorphic reticulosis morphology. Int J Cancer. 1999;81:865-870.
28. Ohno T, Yamaguchi M, Oka K, et al. Frequent expression of CD3 epsilon in CD3 (Leu 4)-negative nasal T-cell lymphomas. Leukemia. 1995;9:44-52.
29. Gaal K, Sun NC, Hernandez AM, et al. Sinonasal NK/Tcell lymphomas in the United States. Am J Surg Pathol. 2000;24:1511-1517.
30. Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood. 2000;95:1900-1910.
31. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
32. Bindl JM, Warnke RA. Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars. Am J Clin Pathol. 1986;85:490-493.
33. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002;161:1557-1565.
34. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9:717-720.
35. Chuang SS, Lin CN, Li CY. Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms. Cancer. 2000;89:1586-1592.
36. Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50:696-702.
37. Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, et al. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol. 1998;11:754-761.
38. Facchetti F, Chan JK, Zhang W, et al. Linker for activation of T cells (LAT), a novel immunohistochemical marker for T cells, NK cells, mast cells, and megakaryocytes: evaluation in normal and pathological conditions. Am J Pathol. 1999;154:1037-1046.
39. Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10:5494-5500.
40. Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer. 2000;89:2106-2116.
41. Li T, Zhang B, Ye Y, et al. Immunohistochemical and genetic analysis of Chinese nasal natural killer/T-cell lymphomas. Hum Pathol. 2006;37:54-60.
42. Liu A, Nakatsuka S, Yang WI, et al. Expression of cell adhesion molecules and chemokine receptors: angioinvasiveness in nasal NK/T-cell lymphoma. Oncol Rep. 2005;13:613-620.
43. Lu D, Lin CN, Chuang SS, et al. T-cell and NK/T-cell lymphomas in southern Taiwan: a study of 72 cases in a single institute. Leuk Lymphoma. 2004;45:923-928.
44. Natkunam Y, Smoller BR, Zehnder JL, et al. Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol. 1999;23:571-581.
45. Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol. 2004;17:1097-1107.
46. Ohshima K, Karube K, Kawano R, et al. Classification of distinct subtypes of peripheral T-cell lymphoma unspecified, identified by chemokine and chemokine receptor expression: analysis of prognosis. Int J Oncol. 2004;25:605-613.
47. Takahara M, Kishibe K, Bandoh N, et al. P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan. Hum Pathol. 2004;35:86-95.
48. Takeshita M, Yamamoto M, Kikuchi M, et al. Angiodestruction and tissue necrosis of skin-involving CD56+ NK/T-cell lymphoma are influenced by expression of cell adhesion molecules and cytotoxic granule and apoptosis-related proteins. Am J Clin Pathol. 2000;113:201-211.
49. Yoshino T, Nakamura S, Suzumiya J, et al. Expression of cutaneous lymphocyte antigen is associated with a poor outcome of nasal-type natural killer-cell lymphoma. Br J Haematol. 2002;118:482-487.
50. Chinen K, Kaneko Y, Izumo T, et al. Nasal natural killer cell/T-cell lymphoma showing cellular morphology mimicking normal lymphocytes. Arch Pathol Lab Med. 2002;126:602-605.
51. Oshimi K. NK cell lymphoma. Int J Hematol. 2002;76(suppl 2):118-121.
52. Buzza MS, Bird PI. Extracellular granzymes: current perspectives. Biol Chem. 2006;387:827-837.
53. Voskoboinik I, Trapani JA. Addressing the mysteries of perforin function. Immunol Cell Biol. 2006;84:66-71.
54. Forch P, Valcarcel J. Molecular mechanisms of gene expression regulation by the apoptosis-promoting protein TIA-1. Apoptosis. 2001;6:463-468.
55. Noorduyn LA, Beljaards RC, Pals ST, et al. Differential expression of the HECA-452 antigen (cutaneous lymphocyte associated antigen, CLA) in cutaneous and non-cutaneous T-cell lymphomas. Histopathology. 1992;21:59-64.
56. Picker LJ, Michie SA, Rott LS, et al. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol. 1990;136:1053-1068.
57. Ponzoni M, Arrigoni G, Gould VE, et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol. 2000;31:220-226.
58. Pals ST, Meijer CJ, Radaszkiewicz T. Expression of the human peripheral lymph node homing receptor (LECAM-1) in nodal and gastrointestinal non-Hodgkin's lymphomas. Leukemia. 1991;5:628-631.
59. Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96:685-690.
60. Lazzeri E, Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5:109-118.